Alopecia areata market set to expand by 2036, due to the emergence of novel drug classes

The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence.

Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.

Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia areata emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]. 

Alopecia Areata Market Summary

• The total alopecia areata treatment market size is expected to grow positively by 2036 in the leading markets.
• The United States accounts for the largest market size of alopecia areata, in comparison to EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
• In 2025, the total diagnosed prevalent cases of alopecia areata in the 7MM were found to be 1.7 million. 
• Leading alopecia areata companies are developing new alopecia areata treatment drugs that can be available in the alopecia areata market in the coming years. 
• The promising alopecia areata therapies in clinical trials include RINVOQ, Bempikibart, Coacillium, ALM 223, Amlitelimab, HCW9302, ALY-101, DR-01, Rezpegaldesleukin, and others.

Key factors driving the growth of the alopecia areata market

• Growing alopecia areata target patient pool
• Approval of JAK inhibitors
• Emergence of OX40L and IL-2 inhibitors
• Expected Launch of Alopecia Areata Therapies: The dynamics of the alopecia areata market are expected to change in the coming years due to the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others.

Alopecia Areata Market Analysis

• The treatment landscape for alopecia areata has evolved into a comprehensive approach that combines pharmacological therapies with supportive care.
• The current market offers a broad range of treatment options, including corticosteroids, immunosuppressants, immunomodulators, and topical sensitizers or irritants.
• Corticosteroids continue to play a central role due to their anti-inflammatory effects, helping reduce immune-mediated attacks on hair follicles.
• Immunosuppressants and immunomodulators are typically used in more severe or treatment-resistant cases to regulate immune activity and prevent further hair loss.
• Topical sensitization therapies, including diphencyprone, work by inducing a mild allergic reaction that diverts the immune response away from hair follicles.
• Topical irritation therapies similarly create controlled irritation to stimulate immune modulation and promote hair regrowth.
• Minoxidil, a vasodilator, is frequently used off-label in alopecia areata to enhance blood flow to hair follicles and support regrowth.
• Dithranol is less commonly used but induces controlled inflammation to alter immune responses and encourage regrowth, mainly in patchy alopecia areata.
• Key market players such as Eli Lilly and Company, Incyte Corporation, Pfizer, and Sun Pharmaceuticals have introduced approved therapies, including OLUMIANT, LITFULO, and LEQSELVI across major markets.
• The growing demand for safer, more effective therapies is creating opportunities for innovative treatments that achieve durable remission without long-term use or serious safety risks.
• The entry of new therapies under development, such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others, are expected to intensify competition and may reduce the market share of established treatments like LITFULO and OLUMIANT over time.